Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 10;7(7):e70039.
doi: 10.1096/fba.2025-00114. eCollection 2025 Jul.

Circulating Inflammatory Proteins Mediate the Causal Effect of Gut Microbiota on Inflammatory Bowel Disease: Bayesian and Mediated Mendelian Randomization

Zeyang Li  1 , Lei Jia  1 , Shengnan Huai  2
Affiliations

Circulating Inflammatory Proteins Mediate the Causal Effect of Gut Microbiota on Inflammatory Bowel Disease: Bayesian and Mediated Mendelian Randomization

Zeyang Li et al. FASEB Bioadv. .

Abstract

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), presents a global public health challenge. Although the relationships between gut microbiota, inflammatory proteins, and IBD are recognized, their causal associations and mediating roles remain unclear. Large-scale genome-wide association study data on 473 gut microbiota, 91 circulating inflammatory proteins, and IBD (including CD and UC) were analyzed. Univariable Mendelian randomization (UVMR), Bayesian Weighted MR (BWMR), mediation MR, and sensitivity analyses were used to explore causal associations and quantify mediating effects. MR results indicate that 24, 20, and 22 gut microbiota exhibit causal effects on IBD (nine protective factors, 15 risk factors), CD (nine protective factors, 11 risk factors) and UC (seven protective factors, 15 risk factors). Three inflammatory proteins (one protective factors, two risk factors) have causal effects on IBD, with five having causal effects on CD (one protective factors, four risk factors) and UC (two protective factors, three risk factors). Mediation analysis reveals that Interleukin-17C levels mediate the causal effects of Acetobacterales and Bifidobacterium on IBD. T-cell surface glycoprotein CD6 isoform levels mediate the causal effect of Faecalibacterium prausnitzii E on CD. Interleukin-17C levels also mediate the causal effects of Acetobacterales on UC and Phocea massiliensis on UC. Gut microbiota and circulating inflammatory proteins play key roles in IBD pathogenesis, with Interleukin-17C and T-cell surface glycoprotein CD6 identified as key intermediates in the causal pathway. These findings provide novel biomarkers and potential therapeutic targets for preventing and treating IBD, CD, and UC.

Keywords: Crohn's disease; Mendelian randomization; circulating inflammatory proteins; gut microbiota; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Concept of study design.
FIGURE 2
FIGURE 2
Mediation effect diagram. (A) The total effect of Gut microbiota on IBD, CD and UC; (c) is derived through UVMR. (B) The total effect is decomposed into: (i) the indirect effect, where “a” represents the effect of Gut microbiota on circulating inflammatory proteins, “b” represents the effect of circulating inflammatory proteins on IBD, CD and UC, and the product method (a*b) is used; (ii) The direct effect (c′ = c—a*b).
FIGURE 3
FIGURE 3
Causal effects of gut microbiota on IBD.
FIGURE 4
FIGURE 4
Causal effects of gut microbiota on CD.
FIGURE 5
FIGURE 5
Causal effects of gut microbiota on UC.
FIGURE 6
FIGURE 6
Causal effects of inflammatory proteins on IBD, CD, and UC.
See this image and copyright information in PMC

References

    1. Rogler G., Singh A., Kavanaugh A., and Rubin D. T. J. G., “Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management,” Gastroenterology 161, no. 4 (2021): 1118–1132. - PMC - PubMed
    1. Baumgart D. C. and Carding S. R., “Inflammatory Bowel Disease: Cause and Immunobiology,” Lancet 369, no. 9573 (2007): 1627–1640. - PubMed
    1. Lennard‐Jones J., “Classification of Inflammatory Bowel Disease,” Scandinavian Journal of Gastroenterology 24, no. sup170 (1989): 2–6. - PubMed
    1. Marks D. J., Harbord M. W., MacAllister R., et al., “Defective Acute Inflammation in Crohn's Disease: A Clinical Investigation,” Lancet 367, no. 9511 (2006): 668–678. - PubMed
    1. Ramos G. P. and Papadakis K. A., “Mechanisms of Disease: Inflammatory Bowel Diseases,” Mayo Clinic Proceedings 94 (2019): 155–165. - PMC - PubMed

LinkOut - more resources